Community Healthcare Trust Valuation
Is CHCT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CHCT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CHCT ($18.39) is trading below our estimate of fair value ($66.89)
Significantly Below Fair Value: CHCT is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CHCT?
Key metric: As CHCT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is CHCT's PS Ratio? | |
|---|---|
| PS Ratio | 4.5x |
| Sales | US$115.61m |
| Market Cap | US$527.82m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 8.6x |
| Enterprise Value/EBITDA | 15.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does CHCT's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.8x | ||
STRW Strawberry Fields REIT | 0.8x | 3.0% | US$618.2m |
UHT Universal Health Realty Income Trust | 5.6x | n/a | US$561.0m |
GMRE Global Medical REIT | 4.2x | 3.2% | US$598.6m |
DHC Diversified Healthcare Trust | 0.4x | 5.3% | US$593.5m |
CHCT Community Healthcare Trust | 4.5x | 12.3% | US$527.8m |
Price-To-Sales vs Peers: CHCT is expensive based on its Price-To-Sales Ratio (4.5x) compared to the peer average (2.8x).
Price to Sales Ratio vs Industry
How does CHCT's PS Ratio compare vs other companies in the US Health Care REITs Industry?
| 4 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
DHC Diversified Healthcare Trust | 0.4x | 5.3% | US$593.54m |
HLTC National Healthcare Properties | 0.6x | n/a | US$220.10m |
NHHS NorthStar Healthcare Income | 0.7x | n/a | US$148.57m |
GBCS Selectis Health | 0.1x | n/a | US$4.17m |
| 4 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Sales vs Industry: CHCT is good value based on its Price-To-Sales Ratio (4.5x) compared to the US Health Care REITs industry average (5.6x).
Price to Sales Ratio vs Fair Ratio
What is CHCT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 4.5x |
| Fair PS Ratio | 3.8x |
Price-To-Sales vs Fair Ratio: CHCT is expensive based on its Price-To-Sales Ratio (4.5x) compared to the estimated Fair Price-To-Sales Ratio (3.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$18.39 | US$21.17 +15.1% | 10.0% | US$25.00 | US$19.00 | n/a | 6 |
| Nov ’25 | US$18.41 | US$21.00 +14.1% | 11.0% | US$25.00 | US$18.00 | n/a | 6 |
| Oct ’25 | US$17.86 | US$20.83 +16.6% | 11.9% | US$25.00 | US$18.00 | n/a | 6 |
| Sep ’25 | US$18.73 | US$23.17 +23.7% | 11.0% | US$28.00 | US$21.00 | n/a | 6 |
| Aug ’25 | US$20.46 | US$26.50 +29.5% | 12.1% | US$30.00 | US$21.00 | n/a | 6 |
| Jul ’25 | US$22.85 | US$28.83 +26.2% | 4.7% | US$30.00 | US$26.00 | n/a | 6 |
| Jun ’25 | US$23.46 | US$29.67 +26.5% | 9.1% | US$35.00 | US$26.00 | n/a | 6 |
| May ’25 | US$25.08 | US$30.00 +19.6% | 9.0% | US$35.00 | US$26.00 | n/a | 6 |
| Apr ’25 | US$26.40 | US$32.67 +23.7% | 7.2% | US$36.00 | US$29.00 | n/a | 6 |
| Mar ’25 | US$27.15 | US$33.67 +24.0% | 9.3% | US$40.00 | US$31.00 | n/a | 6 |
| Feb ’25 | US$25.70 | US$33.80 +31.5% | 10.1% | US$40.00 | US$31.00 | n/a | 5 |
| Jan ’25 | US$26.64 | US$35.50 +33.3% | 13.1% | US$43.00 | US$31.00 | n/a | 6 |
| Dec ’24 | US$27.50 | US$35.50 +29.1% | 13.1% | US$43.00 | US$31.00 | n/a | 6 |
| Nov ’24 | US$27.76 | US$39.83 +43.5% | 15.8% | US$50.00 | US$33.00 | US$18.41 | 6 |
| Oct ’24 | US$29.70 | US$41.67 +40.3% | 12.3% | US$50.00 | US$33.00 | US$17.86 | 6 |
| Sep ’24 | US$33.39 | US$43.40 +30.0% | 8.4% | US$50.00 | US$40.00 | US$18.73 | 5 |
| Aug ’24 | US$35.13 | US$42.20 +20.1% | 5.5% | US$45.00 | US$39.00 | US$20.46 | 5 |
| Jul ’24 | US$33.02 | US$42.25 +28.0% | 5.4% | US$45.00 | US$40.00 | US$22.85 | 4 |
| Jun ’24 | US$32.73 | US$42.25 +29.1% | 5.4% | US$45.00 | US$40.00 | US$23.46 | 4 |
| May ’24 | US$35.95 | US$44.40 +23.5% | 5.8% | US$48.00 | US$42.00 | US$25.08 | 5 |
| Apr ’24 | US$36.60 | US$44.40 +21.3% | 5.8% | US$48.00 | US$42.00 | US$26.40 | 5 |
| Mar ’24 | US$38.74 | US$44.33 +14.4% | 5.3% | US$48.00 | US$42.00 | US$27.15 | 6 |
| Feb ’24 | US$42.51 | US$43.17 +1.5% | 7.1% | US$48.00 | US$38.00 | US$25.70 | 6 |
| Jan ’24 | US$35.80 | US$40.50 +13.1% | 4.2% | US$43.00 | US$38.00 | US$26.64 | 6 |
| Dec ’23 | US$35.53 | US$40.50 +14.0% | 4.2% | US$43.00 | US$38.00 | US$27.50 | 6 |
| Nov ’23 | US$34.19 | US$40.29 +17.8% | 8.9% | US$45.00 | US$33.00 | US$27.76 | 7 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Rayonier
US$4.5b
Rayonier is a leading timberland real estate investment trust with assets located in some of the most productive softwood timber growing regions in the United States and New Zealand.
RYN
US$30.15
7D
0.1%
1Y
-3.0%
Innovative Industrial Properties
US$3.0b
A self-advised Maryland corporation focused on the acquisition, ownership and management of specialized properties leased to experienced, state-licensed operators for their regulated cannabis facilities.
IIPR
US$105.30
7D
2.2%
1Y
31.6%
Park Hotels & Resorts
US$3.0b
Park is one of the largest publicly traded lodging REITs with a diverse portfolio of market-leading hotels and resorts with significant underlying real estate value.
PK
US$14.20
7D
-6.0%
1Y
-1.5%